Memory Concerns and Dementia Biomarkers: The Monza Study in Context

•

Mind & Focus

Share this post

On 29 September 2026, Neurological Sciences published a Monza Brain Health Service study examining health risk factors and blood biomarkers in people reporting cognitive decline.

Researchers assessed people seeking brain-health support

The researchers analyzed baseline data from 186 consecutive attendees at the specialist service in Italy. Of those attendees, 132 were classified as having subjective cognitive decline, or SCD. People could attend through self-referral or through referrals from primary care or memory clinics.

SCD means a person feels that their memory or thinking has declined while performance on standard neuropsychological tests remains normal. It describes an experience of change. It is not itself a diagnosis of dementia.

That distinction matters for someone who notices a persistent change but performs within the normal range on an assessment. The study focused on people bringing those concerns to a service that offered risk assessment and prevention. Our guide to memory concerns alongside normal cognitive test results provides related context.

This was a cross-sectional analysis of starting-point assessments, not a treatment trial. There was no intervention period over which the researchers measured a treatment response. The report examined the participants’ health factors and available clinical measurements at baseline rather than tracking changes over a set follow-up period.

For men reading this after 45, the relevant population detail is the setting: these were people seeking or referred for specialist brain-health assessment. The findings describe that clinical group rather than a community-wide sample.

Sleep impairment and other health factors were common

The Monza researchers reported several potentially modifiable factors among the 132 participants with SCD:

Sleep impairment: 70%.
Smoking: 51%.
Physical inactivity: 50%.
Hypertension: 46%.

Sleep impairment was a broad category. It included self-reported sleep issues, suspected or confirmed REM sleep behavior disorder, or obstructive sleep apnea. The percentage therefore covered a mixture of reported difficulties and possible or established disorders.

For readers interested in that part of the assessment, our coverage of sleep apnea and cognitive concerns addresses a related topic. In the Monza analysis, sleep sat within a wider review that also included activity and cardiovascular health.

The risk score rose with the number of risk factors

Among 92 participants with SCD, a greater number of modifiable risk factors was associated with a higher cumulative risk score. The researchers reported a Spearman correlation of ρ = 0.54, with p < 0.001.

This score combined relative-risk estimates attached to different factors. It was a calculated measure within the study, separate from the blood tests and brain imaging findings. Its construction matters when interpreting what the association means.

Blood testing identified a subgroup with different measurements

Plasma biomarker results were available for 84 of the 132 participants with SCD. Of those tested, 27 participants, or 32%, had p-Tau217 at or above the study’s cutoff of 0.15 pg/mL.

The authors reported additional differences in this subgroup:

Higher p-Tau181 levels.
Higher GFAP levels.
Greater brain atrophy on some MRI measures.

These were the study’s main biological and structural findings. The blood result separated participants into groups for analysis, allowing the researchers to examine how other measurements differed between them.

Participants reported that risk information was useful

The study also examined disclosure of biomarker and risk information to 42 participants with SCD. Almost all described the information as useful and informative. About two-thirds said it increased their motivation to change lifestyle.

The disclosure combined p-Tau217 results with APOE genotype and individualized risk estimates. This part of the report addressed how participants received a package of information, alongside the study’s clinical measurements.

The design limits conclusions about cause and future risk

The authors identified several boundaries that belong alongside the findings. Each affects how much weight the results should carry in a personal health decision.

Cause and progression were not established. A baseline analysis cannot show that sleep problems or other factors caused the memory concerns. It also cannot identify who will later develop dementia or demonstrate that changing a factor prevents it.
The sample was selected through a specialist service. Self-referral and clinical referral limit how widely the results can be applied. These percentages should not be treated as estimates for everyone with memory concerns or for all men after 45.
SCD classification had some uncertainty. Formal neuropsychological testing was incomplete for some participants classified as having SCD, leaving a possibility of misclassification.
The cumulative risk score was not a validated prediction. The authors cautioned that its multiplicative method could inflate estimates when risk factors are not independent. It should not be read as an individual forecast.
The biomarker cutoff was operational. Meeting the p-Tau217 threshold did not confirm amyloid pathology or establish an individual diagnosis. The authors framed the result as a “risk multiplier” rather than an inevitable disease outcome.
The smaller analyses had narrower evidence. Biomarker findings came from 84 participants and disclosure findings from 42. The disclosure evidence was short-term, and the combined information prevented separating the psychological effect of p-Tau217 from the other results.

Reported motivation is also different from sustained behavior change. The authors called for longitudinal follow-up to assess progression and whether risk communication leads to lasting changes.

Persistent concerns belong in a wider clinical review

The practical message is to bring persistent memory or focus changes into a conversation with a qualified clinician. The study gives that conversation a wider health context, with sleep among the most common factors reported in this particular group.

This approach also fits earlier clinical guidance. In its 2024 primary-care guidance, the Alzheimer’s Association recommended structured evaluation when cognitive, behavioral or functional changes are noticed, according to NPACE’s summary. That recommendation covers concerns raised by a patient or by a family member, care partner or clinician.

A useful discussion can begin with a clear account of the change:

What feels different in memory or concentration?
When did the change begin?
Has it affected daily function?

These questions keep the concern grounded in the person’s experience. They also give the clinician a starting point beyond a general statement that memory feels worse.

The wider review can then include the areas highlighted in the Monza study:

Sleep: Current sleep quality and whether a possible sleep disorder needs assessment.
Activity: The person’s usual pattern of physical activity.
Smoking: Current smoking as part of the health review.
Blood pressure: Blood-pressure health and any relevant history of hypertension.

For a man focused on staying capable through work or recreation, this keeps the discussion broader than a single brain-health number. The purpose is to describe the change clearly and review relevant health factors with qualified care. Decisions about assessment and the meaning of any test result belong in that individual clinical context.

What this changes: The Monza study supports existing guidance to assess persistent cognitive concerns alongside wider health, but it does not establish a new standard of clinical practice.

How Everfitguys helps

Men dealing with poor sleep face the daily task of making sense of memory headlines; Everfitguys takes on the editorial work of explaining the evidence. Its reporting puts sleep, stress and slower recovery in context for men 45 and older who want to retain energy and mental sharpness, with uncertainty stated openly and without medical advice.

Read the research